Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
146 hedge funds and large institutions have $1.09B invested in Aimmune Therapeutics in 2019 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 55 increasing their positions, 27 reducing their positions, and 21 closing their positions.
105% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 21
104% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 27
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
17% more funds holding
Funds holding: 125 → 146 (+21)
6% more capital invested
Capital invested by funds: $1.02B → $1.09B (+$65.2M)
20% less call options, than puts
Call options by funds: $13M | Put options by funds: $16.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$22.2M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$17.2M |
| 3 |
Bank of New York Mellon
New York
|
+$12.8M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.4M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$8.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$21.6M |
| 2 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
-$20.1M |
| 3 |
AC
Aisling Capital
New York
|
-$15.3M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$8.23M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$7.28M |
AIMT Hedge Fund Activity: Q3 2019 in Review
146 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q3 2019, worth a combined $1.09B — up 6.4% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new AIMT positions and 21 closed out — a net gain of 22 holders — while 55 added to existing stakes and 27 trimmed.
The largest buyer was Fiera Capital (Canada), adding an estimated $22.2M. The largest seller was Eagle Asset Management, exiting entirely with an estimated $21.6M sold.
- 146 institutional investors held Aimmune Therapeutics (AIMT) as of Q3 2019, up from 125 in Q2 2019.
- Funds reported $1.09B of Aimmune Therapeutics stock for Q3 2019, up 6.4% quarter-over-quarter.
- 43 funds opened new Aimmune Therapeutics positions in Q3 2019 and 21 closed out, a net change of +22 holders.
- The largest Aimmune Therapeutics buyer in Q3 2019 was Fiera Capital (Canada), an estimated $22.2M added.
- The largest Aimmune Therapeutics seller in Q3 2019 was Eagle Asset Management, an estimated $21.6M sold.
Based on aggregated 13F filings for Q3 2019.